PD-L1

[IMV Inc.] IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.

[Oncogene] Scientists discovered that PD-L1 interacted with receptor Frizzled 6 to activate β-catenin signaling and increase β-catenin-targeted gene expression, such as a putative stem cell marker leucine-rich-repeat-containing G-protein-coupled receptor 5.

[Oncogene] Scientists reported that both PD-L1 and JMJD2D were frequently overexpressed in human colorectal cancer specimens with a significant positive correlation.

[Journal of Immunology Research] Scientists generated a therapeutic chimeric protein containing the PD-L1 single-chain variable fragment linked to a cleavable model cytotoxic T lymphocyte epitope: E7 CTL peptide.

[Journal of Immunology] Using a mouse model of sepsis, scientists found that the long noncoding RNA HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) was highly expressed in mice during the late phase of sepsis.

[Oncogene] Investigators showed that oral administration of propranolol delayed tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increased the survival rate of tumor bearing mice.